Market Overview

OXiGENE Says Phase 2 Data on ZYBRESTAT May Produce Transient Cut

Related OXGN
Small Biotech Out Of Favor But Smart Buys Can Pay Off
OXiGENE Announces Results of Promising Preclinical Studies at 2014 AACR Conference

OXiGENE, Inc. (Nasdaq: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the presentation today of data from a Phase 2 trial of ZYBRESTAT (fosbretabulin) in patients with polypoidal choroidal vasculopathy (PCV), which has features similar to age-related macular degeneration (AMD), a degenerative eye disease.

Posted-In: News FDA

 

Most Popular

Related Articles (OXGN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free